A variant of the virus, VSVΔ51, has been engineered to lack the ability to block the host antiviral interferon (IFN) response [15,16], making it highly attenuated in normal cells, which have an intact IFN pathway, and yet highly lytic in cancer cells, which often have defects in this pathway [17]. Here, IFNA1 is linked to cancer.